FDA commissioner addresses AdvaMed board of directors on coronavirus

Dr. Stephen Hahn, the FDA Commissioner, attended a meeting with AdvaMed’s board of directors to discuss the role of both the medical technology industry and the FDA within the coronavirus pandemic.

Hahn wanted to discuss how the organisations could continue their work together to ensure both patients and healthcare providers have the medical equipment they need to address the current global situation.

Chairman and CEO of Stryker, as well as AdvaMed chairman, Kevin Lobo, commented: “I thank FDA commissioner Hahn for taking the time to speak to leaders from across the medical technology industry about how we can best continue our work together to combat COVID-19.

“The medical technology community is doing everything we can to help treat and stop the spread of the coronavirus, and I appreciate the tremendous work the industry is doing.”

AdvaMed president and CEO Scott Whitaker added: “It was important for our board of directors to hear directly from the commissioner on all the work FDA is doing in partnership with our industry to fight COVID-19. We thank him for taking the time and for his remarkable and steady leadership during this time of crisis.

“Dr. Hahn reiterated the importance of the medtech industry to this fight and to the American people who depend on our innovators and manufacturers. We take that responsibility very seriously.

“Our board meeting today focused almost exclusively on the industry’s coronavirus efforts. It was productive, exhaustive, and we look forward to continuing our work to get the medical technologies essential to this fight where they’re needed most.”